AbelZeta Pharma
China - ShanghaiPharmaceutical
Focus: AbelZeta Pharma is a Shanghai-based cell therapy specialist focused on CAR-T, TCR-T, and mesenchymal stem cell (MSC) exosome therapies across oncology, autoimmune disease, and degenerative conditions. The company operates as a clinical-stage developer with a diversified pipeline spanning hematologic malignancies, solid tumors, and regenerative medicine indications.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
Open Jobs
0
About AbelZeta Pharma
AI assessmentNot HiringNo open roles listed right now. Follow AbelZeta Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from AbelZeta Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
38 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
N/A
Clinical Trials (1)
NCT03327285C-CAR011 Treatment in Subjects With ALL After HSCT
N/AHelp build intelligence for AbelZeta Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.